Darren R Veach Selected Research

Tyrosine Kinase Inhibitors

5/2005	PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
8/2002	Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Darren R Veach Research Topics

Disease

22	Neoplasms (Cancer) 01/2023 - 08/2002
9	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2010 - 08/2002
6	Prostatic Neoplasms (Prostate Cancer) 01/2023 - 10/2016
4	Leukemia 05/2006 - 10/2003
2	Peritoneal Neoplasms 01/2023 - 01/2022
2	Glioblastoma (Glioblastoma Multiforme) 11/2016 - 12/2012
2	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 05/2014 - 08/2012
1	Lymphoma (Lymphomas) 01/2023
1	Colorectal Neoplasms (Colorectal Cancer) 01/2020
1	Breast Neoplasms (Breast Cancer) 01/2020
1	Neuroblastoma 01/2020
1	Fibrosis (Cirrhosis) 05/2014
1	Sarcoma (Soft Tissue Sarcoma) 05/2014
1	Brain Neoplasms (Brain Tumor) 12/2012
1	Glioma (Gliomas) 12/2012
1	Polycythemia (Erythrocytosis) 08/2012
1	Disease Progression 05/2006
1	Myeloproliferative Disorders (Myeloproliferative Disorder) 05/2005
1	Splenomegaly 05/2005

Drug/Important Bio-Agent (IBA)

10	Phosphotransferases (Kinase)IBA 11/2020 - 08/2002
10	Imatinib Mesylate (Gleevec)FDA Link 05/2014 - 08/2002
4	Proteins (Proteins, Gene)FDA Link 01/2023 - 05/2005
4	Androgen Receptors (Androgen Receptor)IBA 01/2023 - 10/2016
4	procaine isothiocyanate (PRIT)IBA 01/2023 - 01/2020
3	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 01/2021 - 01/2020
3	Neoplasm Antigens (Tumor Antigens)IBA 01/2021 - 01/2018
3	Dasatinib (BMS 354825)FDA Link 11/2020 - 12/2012
3	AntibodiesIBA 01/2020 - 10/2016
3	AntigensIBA 01/2018 - 10/2016
3	bcr-abl Fusion ProteinsIBA 04/2008 - 08/2002
3	PD 166326IBA 05/2005 - 08/2004
2	Radioisotopes (Radionuclides)IBA 01/2023 - 01/2021
2	LuciferasesIBA 01/2023 - 01/2022
2	IsotopesIBA 01/2021 - 01/2018
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2020 - 05/2005
2	Tyrosine (L-Tyrosine)FDA Link 11/2007 - 05/2005
2	Tyrosine Kinase InhibitorsIBA 05/2005 - 08/2002
1	Biomarkers (Surrogate Marker)IBA 01/2023
1	human ERBB2 proteinIBA 01/2023
1	thiamine triphosphorate (TTP)IBA 01/2021
1	AcidsIBA 01/2021
1	HaptensIBA 01/2020
1	Immunoglobulin G (IgG)IBA 01/2020
1	Prolactin Receptors (Prolactin Receptor)IBA 01/2018
1	J591 monoclonal antibodyIBA 12/2016
1	IodineIBA 12/2016
1	ZirconiumIBA 12/2016
1	Bevacizumab (Avastin)FDA Link 11/2016
1	Platelet-Derived Growth FactorIBA 11/2016
1	Angiogenesis InhibitorsIBA 11/2016
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 10/2016
1	pexidartinibIBA 05/2014
1	MicellesIBA 12/2012
1	FluorineIBA 12/2012
1	Proto-Oncogene Proteins c-sis (Platelet Derived Growth Factor B)IBA 12/2012
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 12/2012
1	2- (4- iodophenylamino)pyrido(2,3- d)pyrimidin- 7- oneIBA 01/2010
1	src-Family KinasesIBA 05/2005
1	Adenosine Triphosphate (ATP)IBA 10/2003

Therapy/Procedure

12	Therapeutics 01/2023 - 08/2002
5	Radioimmunotherapy 01/2023 - 12/2016
2	Radiotherapy 01/2023 - 01/2018
1	Precision Medicine 01/2021
1	Castration 10/2016
1	Molecular Targeted Therapy 05/2014
1	Aftercare (After-Treatment) 01/2010